Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

New Indication Alert: GSK’s Jemperli® (dostarlimab) Plus Chemo FDA-Approved for New Endometrial Cancer Indication

Aug 1, 2024

On 1 August 2024, GSK announced that the FDA has approved Jemperli® (dostarlimab) in combination with carboplatin and paclitaxel followed by Jemperli® as a single agent for treating primary advanced or recurrent endometrial cancer.  This expands the previous indication for Jemperli® for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer.  GSK reports that the new indication includes MMRp/MSS tumours, which represent the majority of endometrial cancer cases.

In June 2022, a study sponsored by GSK and presented at the ASCO annual meeting reported on a small trial of 14 patients with dMMR rectal cancer in which 6 months of dostarlimab treatment led to clinical complete responses in 100% of patients.